Most founders treat debt as the thing you do after the equity story falls apart. That instinct is wrong often enough that it's worth naming the three situations where repayable money is actually the better instrument, not the consolation prize. Business Chain tracks 6 repayable-finance programmes and 12 that blend debt with grants or revenue-share, and the terms on them are more specific, and often better, than most founders assume.
The three situations where repayable money is the right call
- A known cost with a known return: you can model exactly what an extra dollar of ad spend or inventory produces, so the cost of capital is a math problem, not a bet.
- A bridge to a committed round: you have a signed term sheet and a wire that's weeks away, not an idea you're hoping to fund into existence.
- Revenue that already exists: the lender is underwriting your MRR or ARR, not your pitch deck, which means the approval decision is about your bank statements, not your narrative.
Wayflyer is built for the first case: it funds 5.000 €–20 Mio. € against revenue you can already attribute to a specific cost, inventory or ad spend, and the size of the facility scales with the size of the return you can show. Uncapped, which runs $100K to $2M on a rolling basis and was checked 9 October 2026, is a reasonable bridge facility if your term sheet is signed and you just need the weeks between signature and wire covered without reopening cap table conversations. And Founderpath is squarely the third case: its 2026 average deal size is $750,000, underwritten against SaaS revenue that already exists, and it told the market it would invest $10M–$20M in October, which tells you the appetite is there if your numbers are real.
What the terms in our catalogue actually look like
Levenue will take up to 35% of your future ARR upfront, which means you're trading a slice of revenue you haven't collected yet for cash today, and the math only works if that revenue was coming anyway. Gilion doesn't publish a fixed amount, it sizes non-dilutive funding for SaaS businesses against your own metrics. Karmen works the same way, you enter your annual turnover and the facility is set individually from there rather than from a published range.
Here's the part founders skip past: some of this market is genuinely zero-interest because it isn't a loan at all, it's public non-dilutive money with reporting requirements instead of a coupon rate. The MassVentures START Grant pays $100,000 to $500,000, non-dilutive, with its application window reopening February 1, 2027. SCRA's Startup & Acceleration Grants go up to $25,000 at the startup stage or $50,000 at acceleration, non-dilutive, accepted on a rolling basis. EXIST's Gründerstipendium pays up to EUR 30,000 plus a monthly stipend, non-dilutive, though we couldn't confirm current application status automatically, so check the page before you build a runway plan around it. NC IDEA runs $10,000 at the MICRO tier or $50,000 at SEED, non-dilutive, same caveat on status. HTDC's Hawaii SBIR Matching Grant covers up to 50% of a Phase I SBIR award, non-dilutive, with application dates also unconfirmed on the programme's own site. And if you're building on Web3 rails, Fireblocks' Blockchain Grants are capped at 25% of what you already pay Fireblocks in annual fees, which is a strange but real way to get a discount on infrastructure you're already using.
What a personal guarantee means, and when to refuse one
A personal guarantee means that if the company can't pay, you personally owe the balance, out of your savings, your house, whatever the contract names. Revenue-based structures like the ones above are usually built to avoid this because repayment comes out of revenue automatically, as a percentage of what comes in, not as a fixed sum chased through your personal assets. If a lender offering a revenue-share or revenue-based facility also wants a personal guarantee, that's two forms of collection stacked on top of each other, and you should refuse it. A guarantee might be defensible on a small, short, fully collateralized bridge where you understand exactly what triggers it. It is never defensible on a facility that's already pricing its risk by taking a cut of your revenue stream.
The honest case against
A repayment schedule doesn't read your Slack. If churn spikes the month after you draw against a $750,000 Founderpath-sized facility, the draw is still outstanding. If Levenue has 35% of your future ARR and that ARR shrinks, the percentage doesn't shrink with it, you owe the same share of a smaller number for longer. Grants don't have this problem, which is exactly why they're worth the slower timelines, a MassVentures window that doesn't reopen until February 1, 2027 is annoying but it never asks for money back. Debt is the right call when you can already see the revenue that repays it. It's the wrong call when you're hoping the product gets there in time. The full list, six repayable programmes and the twelve that blend forms, is at businesschain.us/funds/type/loan.